Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

Conditions

• Diabetic Kidney Disease (DKD)

Eligibility Criteria

Sex

ALL

Age

18 Years - 80 Years

Healthy Volunteers

Not accepted

Interventions

• ALN-ANG3 — DRUG
  Administered per the protocol
• Evinacumab — DRUG
  No longer being administered
• Placebo — DRUG
  Administered per the protocol

Study Details

This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times

Key Dates

First listed

Dec 9, 2025

Start date

Jan 9, 2026

Status verified

Sep 2026

Primary completion

Oct 13, 2028

Completion

Oct 13, 2028

Study Design

Enrollment

195 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: ALN-ANG3 + evinacumab
  This arm has been closed
• Experimental: ALN-ANG3
• Placebo Comparator: Placebo

Primary Outcome Measure

Percent Change in Urine Albumin to Creatinine Ratio (UACR) [ Time Frame: Baseline to Week 24 ]

Central Contacts

• Clinical Trials Administrator
  844-734-6643
  [email protected]

Locations (58)

Find similar trials in Huntsville, AL